AP-HP, Hôpitaux universitaires Paris-Seine-Saint-Denis, Hôpital Avicenne, Service d’hépatologie, 93000 Bobigny
Université Paris Nord, UFR SMBH, Bobigny
Inserm, Université de Paris, Sorbonne Université, Centre de recherche des Cordeliers, UMR 1138, Functional Genomics of Solid Tumors laboratory, 75006 Paris
Inserm, Université de Paris, Centre de recherche sur l’inflammation, UMR 1149 « De l’inflammation au cancer », Paris
Correspondance : E. Gigante
The global epidemiology of hepatocellular carcinoma in recent decades was marked by the emergence of non-alcoholic fatty liver disease (NAFLD), parallel to the expansion of obesity and type 2 diabetes. NAFLD represents today the main cause of chronic hepatopathy worldwide, ahead of viral hepatitis and alcohol consumption, as well as one of the principal aetiologies of hepatocellular carcinoma (HCC), especially in Western countries. In this review, we sought to present the latest data on the epidemiology of dysmetabolic hepatopathy and hepatocellular carcinoma resulting from NAFLD; and to discuss the main clinical and molecular features leading to the progression of liver disease and the development of HCC in NAFLD. In a dedicated paragraph, we discuss the therapeutic specificities of HCC developed on NASH. The emerging concept of metabolic fatty liver disease (MAFLD) and its association with the development of HCC are also introduced.